Addex Therapeutics Financials

ADXN Stock  USD 0.70  0.05  7.69%   
Addex Therapeutics Average Assets are very stable at the moment as compared to the past year. Addex Therapeutics reported last year Average Assets of 12.4 Million. As of 1st of June 2023, Average Equity is likely to grow to about 12.3 M, while Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop (20.7 M).
With this module, you can analyze Addex financials for your investing period. You should be able to track the changes in Addex Therapeutics individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.

Addex Most Recent Estimates

Diluted Eps
Earnings Share
Understanding current and past Addex Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Addex Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Addex Therapeutics' assets may result in an increase in income on the income statement.
The financial analysis of Addex Therapeutics is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Addex Therapeutics includes many different criteria found on its balance sheet. For example, investors should never minimize Addex Therapeutics' ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Addex Therapeutics' cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Addex Therapeutics.

Cash and Equivalents

7.14 Million

Evaluating Addex Therapeutics' financials involves analyzing a range of financial metrics and ratios to gain insights into the company's financial health and performance. However, considering all of Addex Therapeutics' profitability, liquidity ratios, and efficiency indicators at the same time could be an enormous task, and our Financial Distress score can provide you with a snapshot of the Addex Therapeutics' relative financial performance

Chance Of Distress

Over 81

Addex Therapeutics has more than 81 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Addex Therapeutics stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity.
Please note, Addex Therapeutics' odds of distress score SHOULD NOT be confused with the real chance of Addex Therapeutics filing for bankruptcy protection for chapters 7, 11, 12, or 13. We define Financial Distress as an operational condition where an entity such as Addex is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from public financial statements and analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors considered include Addex Therapeutics' liquidity analysis, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
More Info
The data published in Addex Therapeutics' official financial statements usually reflect Addex Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Addex Therapeutics. For example, before you start analyzing numbers published by Addex accountants, it's critical to develop an understanding of what Addex Therapeutics' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Addex Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Addex Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Addex Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Addex Therapeutics. Please utilize our Beneish M Score to check the likelihood of Addex Therapeutics' management manipulating its earnings.

Addex Therapeutics Company Summary

Addex Therapeutics competes with Dice Molecules, Equillium, DiaMedica Therapeutics, Denali Therapeutics, and VBI Vaccines. Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system disorders in Switzerland. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland. Addex Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people.
Foreign Associate
Healthcare, Biotechnology
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
Business AddressChemin des Mines,
BenchmarkNYSE Composite
Phone41 22 884 1555
CurrencyUSD - US Dollar
You should never invest in Addex Therapeutics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Addex Stock, because this is throwing your money away. Analyzing the key information contained in Addex Therapeutics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Addex Therapeutics Key Financial Ratios

Generally speaking, Addex Therapeutics' financial ratios allow both analysts and investors to convert raw data from Addex Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Addex Therapeutics over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Addex Therapeutics reports annually and quarterly.

Addex Therapeutics Key Balance Sheet Accounts

201820192020202120222023 (projected)
Total Assets42.21 M33.03 M20.18 M22.54 M8.28 M8.5 M
Current Assets42.15 M32.39 M19.49 M21.94 M7.83 M8.03 M
Assets Non Current63.27 K639.88 K692.25 K600.01 K453.09 K475.68 K
Cash and Equivalents41.67 M31.54 M18.7 M20.48 M6.96 M7.14 M
Investments62.39 K82.88 K124.07 K75.05 K57.52 K70.83 K
Investments Current7.98 K13.97 K64.93 K17.14 K3.17 K3.25 K
Total Liabilities2.97 M7.5 M5.57 M5.61 M3.37 M4.35 M
Current Liabilities2.33 M5.68 M3.62 M4.13 M3.28 M3.71 M

Addex Therapeutics Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what Addex Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201820192020202120222023 (projected)
Consolidated Income(1.64 M)(14.78 M)(12.86 M)(15.35 M)(20.8 M)(21.35 M)
Earning Before Interest and Taxes EBIT(1.42 M)(14.57 M)(12.21 M)(15.29 M)(20.49 M)(21.03 M)
Earning Before Interest and Taxes USD(1.45 M)(15.02 M)(13.87 M)(16.8 M)(22.03 M)(22.61 M)
Interest Expense220.17 K213.32 K650.63 K63.01 K313.26 K310.16 K
Net Income(1.64 M)(14.78 M)(12.86 M)(15.35 M)(20.8 M)(21.35 M)
Net Income Common Stock(1.64 M)(14.78 M)(12.86 M)(15.35 M)(20.8 M)(21.35 M)
Net Income Common Stock USD(1.68 M)(15.24 M)(14.61 M)(16.87 M)(22.37 M)(22.96 M)
Operating Expenses8.13 M17.44 M16.12 M18.66 M21.97 M19.86 M
Operating Income(2.08 M)(14.67 M)(12.51 M)(15.74 M)(20.54 M)(21.08 M)
Research and Development Expense4.92 M12.45 M10.37 M12.84 M14.67 M13.3 M
Selling General and Administrative Expense3.21 M4.98 M5.75 M5.82 M7.3 M6.56 M

Addex Therapeutics Key Cash Accounts

Cash flow analysis captures how much money flows into and out of Addex Therapeutics. It measures of how well Addex is doing because it can show the actual money that comes into and out of the company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Addex Therapeutics brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Addex had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Addex Therapeutics has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
201820192020202120222023 (projected)
Capital Expenditure(9.05 K)(28.46 K)(59.41 K)(31.55 K)(581)(626.87)
Depreciation Amortization and Accretion2.94 K333.84 K378.75 K347.61 K323.14 K305.31 K
Net Cash Flow or Change in Cash and Cash Equivalents39.08 M(9.99 M)(12.19 M)1.67 M(13.33 M)(13.68 M)
Issuance Purchase of Equity Shares40.48 M5.99 K720.01 K13.57 M1.12 M1.15 M
Net Cash Flow from Financing37.39 M(463.69 K)46.4 K16.4 M3.1 M3.18 M
Net Cash Flow from Investing(56.37 K)(43.25 K)(59.41 K)(30.31 K)2.97 K3.21 K
Net Cash Flow from Operations1.75 M(9.48 M)(12.18 M)(14.71 M)(16.44 M)(16.87 M)
Effect of Exchange Rate Changes on Cash10.47 K(144.3 K)(648.68 K)122.47 K(196.22 K)(211.72 K)

Addex Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Addex Therapeutics's current stock value. Our valuation model uses many indicators to compare Addex Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Addex Therapeutics competition to find correlations between indicators driving Addex Therapeutics's intrinsic value. More Info.
Addex Therapeutics is number one stock in gross profit category among related companies. It is number one stock in price to sales category among related companies . The ratio of Gross Profit to Price to Sales for Addex Therapeutics is about  140,566 . Addex Therapeutics Gross Profit is very stable at the moment as compared to the past year. Addex Therapeutics reported last year Gross Profit of 1.42 Million. Comparative valuation analysis is a catch-all model that can be used if you cannot value Addex Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Addex Therapeutics' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Addex Therapeutics' earnings, one of the primary drivers of an investment's value.

Addex Therapeutics Systematic Risk

Addex Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Addex Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Addex Therapeutics correlated with the market. If Beta is less than 0 Addex Therapeutics generally moves in the opposite direction as compared to the market. If Addex Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Addex Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Addex Therapeutics is generally in the same direction as the market. If Beta > 1 Addex Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.

About Addex Therapeutics Financials

What exactly are Addex Therapeutics Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Addex Therapeutics' income statement, its balance sheet, and the statement of cash flows. Potential Addex Therapeutics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Addex Therapeutics investors may use each financial statement separately, they are all related. The changes in Addex Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Addex Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

Steps to analyze Addex Therapeutics Financials for Investing

There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Addex Therapeutics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Addex has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.
In summary, you can determine if Addex Therapeutics' financials are consistent with your investment objective using the following steps:
  • Review Addex Therapeutics' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
  • Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
  • Study the cash flow inflows and outflows to understand Addex Therapeutics' liquidity and solvency.
  • Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
  • Compare Addex Therapeutics' financials to those of its peers to see how it stacks up and identify any potential red flags.
  • Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Addex Therapeutics' stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to analyze the leading stock market indicators., conduct additional research and seek professional advice if needed.

Addex Therapeutics June 1, 2023 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Addex Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Addex Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Addex Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Addex Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Addex Therapeutics's daily price indicators and compare them against related drivers.
Check out Trending Equities to better understand how to build diversified portfolios. To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide. You can also try Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Addex Stock analysis

When running Addex Therapeutics' price analysis, check to measure Addex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Addex Therapeutics is operating at the current time. Most of Addex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Addex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Addex Therapeutics' price. Additionally, you may evaluate how the addition of Addex Therapeutics to your portfolios can decrease your overall portfolio volatility.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Is Addex Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Addex Therapeutics. If investors know Addex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Addex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
Revenue Per Share
Quarterly Revenue Growth
Return On Assets
Return On Equity
The market value of Addex Therapeutics is measured differently than its book value, which is the value of Addex that is recorded on the company's balance sheet. Investors also form their own opinion of Addex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Addex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Addex Therapeutics' market value can be influenced by many factors that don't directly affect Addex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Addex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Addex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Addex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party. Check out Trending Equities to better understand how to build diversified portfolios. To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.